


The investment objective is to provide above average capital growth over the medium to long term by investment in a portfolio of the securities of companies in any European country, including Turkey, but excluding the United Kingdom.
| Name | % Net Assets |
|---|---|
| Novartis | 5.2% |
| Roche Holdings Genusscheine | 4.7% |
| Banco Santander | 4.6% |
| Nestle | 4.1% |
| Unicredit | 3.5% |
| SAP | 3.3% |
| Bayer | 3.2% |
| ABB | 3.1% |
| Carrefour | 3.0% |
| E.on | 3.0% |
| Key | % Net Assets |
|---|---|
| 5.2% | |
| 4.7% | |
| 4.6% | |
| 4.1% | |
| 81.4% |
| Date | 20-Aug-2025 |
|---|---|
| NAV | 254.50p |
| Currency | GBP |
| Change | 0.80p |
| % | 0.32% |
| YTD change | 37.10p |
| YTD % | 17.07% |
| Fund Inception | 31/01/2000 |
|---|---|
| Fund Manager | Thomas Digenen (UBS Asset Management Ltd) |
| TER | - |
| Minimum Investment | |
|---|---|
| Initial | £1000 |
| Additional | £500 |
| Savings | £50 |
| Charges | |
|---|---|
| Initial | 5.00% |
| Annual Mang't | 1.38% |
| Exit | n/a |
| Name | % |
|---|---|
| No risk data available. | |
You are here: research